Clinical trials: Residual
Acute Myeloblastic Leukemia
Treatment of Acute Myeloblastic Leukemia in Younger Patients
study of the value of the cytogenetics and the monitoring of the residual minimum disease in the standard treatment of acute myeloblastic leukemia.
- Trial name
- NCT00390715
- Testing
- chemotherapy
- Where
- 42 sites in Spain
- Volunteers
- 600 people
- Sponsor
- PETHEMA Foundation
Type I Hypersensitivity
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00118625
- Testing
- Tree MATA MPL
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Allergy Therapeutics
Neuromuscular Blockade
Reversal of Residual Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine
The aim of this study is to estimate the optimal dose of sugammadex and neostigmine reversal of a vecuronium-induced residual neuromuscular block at train-of-four ratio 0.3.
- Trial name
- NCT03656614
- Testing
- Sugammadex, Neostigmine, Saline 0.9%
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Guangzhou General Hospital of Guangzhou Military Command
Leukemia
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with a TKI that you are already taking (such as Gleevec, Sprycel, or…
- Trial name
- NCT01460498
- Testing
- Azacitidine (AZA), Tyrosine kinase inhibitor (TKI), Azacitidine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Testicular Cancer
Circulating microRNAs in Small Testicular Masses and Retroperitoneal Post-chemotherapy Residual Masses.
The purpose of this study is to evaluate the diagnostic performance of circulating microRNAs in detecting the presence of germ cell cancer in patients with small testicular mass or retroperitoneal post-chemotherapy residual mass…
- Trial name
- SEARCH-1 (NCT06620016)
- Testing
- Circulating microRNAs.
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Multiple Myeloma
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
This is a multicenter, single arm, open-label, Phase 2 study in mutiple myeloma with newly diagnosed and treatment-naïve participants for whom high-dose therapy and autologous stem cell transplantation is part of the intended…
- Trial name
- TAURUS (NCT06189833)
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 31 sites in Austria, Germany and 3 more
- Volunteers
- 200 people
- Sponsor
- Stichting European Myeloma Network
Malaria
Transmission Dynamics of Residual and Re-emerging Malaria in the Amazon: Defining a Roadmap to Malaria Elimination
A population baseline longitudinal study in a major residual malaria hotspot in Brazil to: 1. identify risk factors for residual malaria infection and disease at individual and household level, 2.
- Trial name
- NCT03689036
- Where
- Brazil
- Volunteers
- 2,000 people
- Sponsor
- Oswaldo Cruz Foundation
Elective Procedures Requiring Mechanical Ventilation
Evaluation of Novel Cardio-Pulmonary Physiological Monitor, the VQm PHM™, for Acute Care Medicine
This is a prospective, observational study to assess agreement of pulmonary health parameters measured by a new non-invasive physiologic monitor, the VQm pulmonary health monitor (PHM)™ with clinical gold standards.
- Trial name
- NCT04730063
- Testing
- VQm PHM™
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rostrum Medical Innovations Inc.
Acute Myeloid Leukemia
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk…
- Trial name
- NCT05554393
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 187 sites in United States, Canada and 1 more
- Volunteers
- 153 people
- Sponsor
- National Cancer Institute (NCI)
High-risk Diffuse Large B-cell Lymphoma
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
The study will estimate the MRD-negative response rate after treatment with blinatumomab in subjects with high-risk DLBCL who are MRD-positive following aHSCT.
- Trial name
- NCT03298412
- Testing
- Blinatumomab
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 10 people
- Sponsor
- Amgen
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Prostate Carcinoma
An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion…
- Trial name
- ECLIPSE (NCT07185165)
- Testing
- Computed Tomography, Fluorine F 18 Flotufolastat, Positron Emission Tomography
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Dupuytren's Contracture
Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease
OBJECTIVES: Evaluate the safety and efficacy of collagenase in improving flexion deformity, range of motion, and grip strength in patients with residual Dupuytren's disease.
- Trial name
- NCT00004409
- Testing
- collagenase
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- State University of New York
Minimal Residual Disease, Adjuvant Chemotherapy
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
To find out if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have "positive" ctDNA tests for MRD (meaning there is evidence of MRD based on this…
- Conditions
- Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib
- Trial name
- NCT07136077
- Testing
- Tislelizumab, Fruquintinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and…
- Trial name
- NCT04419519
- Testing
- Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Periodontitis
Hyaluronan in the Treatment of Residual Pockets in Periodontitis Patients.
Aim To evaluate the clinical and microbiological effects of a hyaluronan (HY) as adjunct to scaling and root planning of residual pockets during supportive periodontal therapy.
- Trial name
- NCT04792541
- Testing
- HY containing gel; GUM® Afta Clear Gel, Sunstar, saline solution
- Volunteers
- 66 people
- Sponsor
- Malmö University
Endoscopic Full Thickness Resection (EFTR), Residual /Recurrent Colorectal Lesion
Technical Failure During Colorectal Endoscopic Full Thickness Resection (EFTR): The "Through Thick and Thin" Study
Among advanced resection techniques, endoscopic full thickness resection (EFTR) allows closure and full-thickness resection by the use of the non-exposed full thickness resection device (FTRD).
- Conditions
- Endoscopic Full Thickness Resection (EFTR), Residual /Recurrent Colorectal Lesion, Full-thickness Resection Device (FTRD), Colorectal Adenoma
- Trial name
- NCT05913453
- Where
- Italy
- Volunteers
- 77 people
- Sponsor
- Azienda Unità Sanitaria Locale della Romagna
Phantom Limb Pain, Postoperative Pain
Postoperative Peripheral Nerve Stimulation for Management of Post-amputation Pain
Limb loss is frequently associated with postamputation pain that can be challenging to treat and often involves opioids. Advances in the field of neuromodulation has led to development of an intentionally reversible percutaneous…
- Conditions
- Phantom Limb Pain, Postoperative Pain, Neuroma, Acute Pain
- Trial name
- NCT03484429
- Testing
- Peripheral nerve stimulation, Standard Medical Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Postoperative Residual Curarization, Liver Transplantation
Sugammadex/Neostigmine and Liver Transplantation
Cirrhotic patients undergoing liver transplantation are at very high risk of post operative complication such as post-operative residual curarization.
- Trial name
- NCT02697929
- Testing
- sugammadex, Neostigmine
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliera S. Maria della Misericordia
Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission.
- Conditions
- Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder, Acute Myeloid Leukemia
- Trial name
- NCT04062266
- Testing
- Azacitidine, Venetoclax
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.